Pub Date : 2025-01-01DOI: 10.1177/10732748241310936
Mohammad A Saghiri, Ravinder S Saini, Artak Heboyan
Background: Oral cancer remains 1 of the biggest health care challenges; it has a poor response to treatment, and treatment often results in severe side effects. Nano-targeted drug carrier-assisted drug delivery systems can improve the benefits of targeted drug delivery and treatment efficacy. A systematic review and meta-analysis was conducted to investigate the effect of targeted nano carrier drug delivery systems on the management of oral cancer.
Methods: A comprehensive literature search was performed using PubMed, ScienceDirect, the Cochrane Library, Google Scholar, and Scopus using PRISMA guidelines, to identify relevant in vitro and in vivo (human) studies. Studies evaluating the impact of nanocarrier-based delivery systems on oral cancer cells or human models were selected. Pooled effect sizes were calculated using random-effects models via RevMan 5.4, and heterogeneity among studies was assessed.
Results: After full-text assessment, 15 research articles were included [14 in vitro studies and 1 randomized controlled trial (RCT)]. In the meta-analysis, the pooled data (IC50) for the impact of the nanocarrier delivery system vs control on oral cancer was -7.67 (95% CI: -41.77, 26.43), with a high heterogeneity (I2 = 92%, P < 0.00001). Moreover, in vitro studies had a medium risk of bias, while the RCT had some concerns in the randomization domain.
Conclusion: Nanocarrier-based drug delivery has been found to be a superior approach compared to drug delivery in free form, increasing the efficacy and safety of oral cancer treatment.
{"title":"Cytotoxicity of Nanocarrier-Based Drug Delivery in Oral Cancer Therapy: A Systematic Review and Meta-Analysis.","authors":"Mohammad A Saghiri, Ravinder S Saini, Artak Heboyan","doi":"10.1177/10732748241310936","DOIUrl":"10.1177/10732748241310936","url":null,"abstract":"<p><strong>Background: </strong>Oral cancer remains 1 of the biggest health care challenges; it has a poor response to treatment, and treatment often results in severe side effects. Nano-targeted drug carrier-assisted drug delivery systems can improve the benefits of targeted drug delivery and treatment efficacy. A systematic review and meta-analysis was conducted to investigate the effect of targeted nano carrier drug delivery systems on the management of oral cancer.</p><p><strong>Methods: </strong>A comprehensive literature search was performed using PubMed, ScienceDirect, the Cochrane Library, Google Scholar, and Scopus using PRISMA guidelines, to identify relevant in vitro and in vivo (human) studies. Studies evaluating the impact of nanocarrier-based delivery systems on oral cancer cells or human models were selected. Pooled effect sizes were calculated using random-effects models via RevMan 5.4, and heterogeneity among studies was assessed.</p><p><strong>Results: </strong>After full-text assessment, 15 research articles were included [14 in vitro studies and 1 randomized controlled trial (RCT)]. In the meta-analysis, the pooled data (IC<sub>50</sub>) for the impact of the nanocarrier delivery system vs control on oral cancer was -7.67 (95% CI: -41.77, 26.43), with a high heterogeneity (<i>I</i><sup><i>2</i></sup> = 92%, <i>P</i> < 0.00001). Moreover, in vitro studies had a medium risk of bias, while the RCT had some concerns in the randomization domain.</p><p><strong>Conclusion: </strong>Nanocarrier-based drug delivery has been found to be a superior approach compared to drug delivery in free form, increasing the efficacy and safety of oral cancer treatment.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241310936"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-06-04DOI: 10.1177/10732748251347731
Jim P Stimpson, Sungchul Park, Anna M Morenz, Tami Gurley, Fernando A Wilson
IntroductionThis cross-sectional study examined the relationship between paid sick leave and colorectal cancer (CRC) endoscopy screening among employed adults, including the examination of potential pathways.MethodsWe analyzed data from 15,352 employed adults aged 45-75 from the 2021 and 2023 National Health Interview Survey. A generalized structural equation model (GSEM) assessed the direct and indirect pathways between employment status (full-time vs part-time), paid sick leave, health insurance, usual source of care, and CRC endoscopy screening. Survey weights were applied to ensure nationally representative estimates.ResultsFull-time employment was positively associated with paid sick leave (OR = 6.57, 95% CI: 5.85, 7.38) and health insurance (OR = 1.30, 95% CI: 1.07, 1.59). Paid sick leave increased the likelihood of having a usual source of care (OR = 1.57, 95% CI: 1.31, 1.87) and was directly associated with CRC screening (OR = 1.15, 95% CI: 1.03, 1.28). Health insurance increased the likelihood of having a usual source of care (OR = 5.32, 95% CI: 4.30, 6.58) and CRC screening (OR = 3.22, 95% CI: 2.58, 4.02). Usual source of care was also associated with CRC screening (OR = 3.53, 95% CI: 2.89, 4.32).ConclusionsPaid sick leave was associated with CRC endoscopy utilization both directly and indirectly through improved healthcare access. Workplace policies that expand paid sick leave, alongside efforts to strengthen insurance coverage and primary care access, may reduce barriers to CRC endoscopy screening and improve population health.
{"title":"Examining Employment Status, Paid Sick Leave, and Access to Care in Relation to Colorectal Cancer Screening Among U.S. Workers: A Structural Equation Modeling Approach.","authors":"Jim P Stimpson, Sungchul Park, Anna M Morenz, Tami Gurley, Fernando A Wilson","doi":"10.1177/10732748251347731","DOIUrl":"10.1177/10732748251347731","url":null,"abstract":"<p><p>IntroductionThis cross-sectional study examined the relationship between paid sick leave and colorectal cancer (CRC) endoscopy screening among employed adults, including the examination of potential pathways.MethodsWe analyzed data from 15,352 employed adults aged 45-75 from the 2021 and 2023 National Health Interview Survey. A generalized structural equation model (GSEM) assessed the direct and indirect pathways between employment status (full-time vs part-time), paid sick leave, health insurance, usual source of care, and CRC endoscopy screening. Survey weights were applied to ensure nationally representative estimates.ResultsFull-time employment was positively associated with paid sick leave (OR = 6.57, 95% CI: 5.85, 7.38) and health insurance (OR = 1.30, 95% CI: 1.07, 1.59). Paid sick leave increased the likelihood of having a usual source of care (OR = 1.57, 95% CI: 1.31, 1.87) and was directly associated with CRC screening (OR = 1.15, 95% CI: 1.03, 1.28). Health insurance increased the likelihood of having a usual source of care (OR = 5.32, 95% CI: 4.30, 6.58) and CRC screening (OR = 3.22, 95% CI: 2.58, 4.02). Usual source of care was also associated with CRC screening (OR = 3.53, 95% CI: 2.89, 4.32).ConclusionsPaid sick leave was associated with CRC endoscopy utilization both directly and indirectly through improved healthcare access. Workplace policies that expand paid sick leave, alongside efforts to strengthen insurance coverage and primary care access, may reduce barriers to CRC endoscopy screening and improve population health.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251347731"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-06-18DOI: 10.1177/10732748251349919
Youcef Derbal
Adaptive combination therapy is deemed the most intuitive strategy to thwart therapeutic resistance through dynamic treatment tuning that accounts for cancer evolutionary dynamics. However, higher accuracy and reliability of treatment response predictions would be needed, in addition to the need for clinically feasible models of adaptive combination therapy that consider newly approved therapeutics and the growing multimodal data being available about cancer. Grounded in nonlinear system control theory, this review offers a perspective on exploiting GenAI learning and inferencing capabilities to predict treatment response and recommend treatments in the context of adaptive cancer therapy. Results from nonlinear system identification, control theory and deep learning are integrated within an adaptive cancer control framework to leverage the continuously expanding data about cancer and its treatment towards GenAI-enhanced adaptive therapy. The resulting models and their analysis contribute to a much-needed conceptual clarity about the research and translational pathways that would be needed to realize GenAI-assisted cancer treatments. In particular, they underscore that access to clinical data, deep learning opacity, and clinical validation present critical challenges that require adequate attention to pave the way towards acceptance and integration of GenAI in real-world oncology workflows.
{"title":"Generative AI - Assisted Adaptive Cancer Therapy.","authors":"Youcef Derbal","doi":"10.1177/10732748251349919","DOIUrl":"10.1177/10732748251349919","url":null,"abstract":"<p><p>Adaptive combination therapy is deemed the most intuitive strategy to thwart therapeutic resistance through dynamic treatment tuning that accounts for cancer evolutionary dynamics. However, higher accuracy and reliability of treatment response predictions would be needed, in addition to the need for clinically feasible models of adaptive combination therapy that consider newly approved therapeutics and the growing multimodal data being available about cancer. Grounded in nonlinear system control theory, this review offers a perspective on exploiting GenAI learning and inferencing capabilities to predict treatment response and recommend treatments in the context of adaptive cancer therapy. Results from nonlinear system identification, control theory and deep learning are integrated within an adaptive cancer control framework to leverage the continuously expanding data about cancer and its treatment towards GenAI-enhanced adaptive therapy. The resulting models and their analysis contribute to a much-needed conceptual clarity about the research and translational pathways that would be needed to realize GenAI-assisted cancer treatments. In particular, they underscore that access to clinical data, deep learning opacity, and clinical validation present critical challenges that require adequate attention to pave the way towards acceptance and integration of GenAI in real-world oncology workflows.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251349919"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-07-02DOI: 10.1177/10732748251357471
Aybala Nur Ucgul
{"title":"Letter to the Editor: Do Nutritional and Inflammatory Indices Predict Response in Geriatric Gastric Cancer Patients Treated With Neoadjuvant FLOT Regimen?","authors":"Aybala Nur Ucgul","doi":"10.1177/10732748251357471","DOIUrl":"10.1177/10732748251357471","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251357471"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The leucine-rich pentatricopeptide repeat-containing (LRPPRC) protein, a member of the pentatricopeptide repeat (PPR) family, is a mitochondria-associated protein that regulates various biological processes, including cell cycle progression and mitochondrial gene translation. LRPPRC has also been identified as an important causative gene in several mitochondrial diseases. N6-methyladenosine (m6A) is the most prevalent and extensive modification of mRNA in eukaryotes, playing a significant role in cellular proliferation, differentiation, and oncogenesis. As an m6A regulator, LRPPRC has been shown to play an important role in the development of various human metabolic diseases and malignant tumors. This review mainly focuses on summarizing the biological roles of LRPPRC in a variety of human malignant tumors, emphasizing the molecular mechanisms LRPPRC is involved in and its potential impact on tumor prognosis.
{"title":"The Biological Role of LRPPRC in Human Cancers.","authors":"Jiaxin Tang, Jing Li, Shiyu Qin, Yu Xiao, Jiaxin Liu, Xian Chen, Yunyuan Zhang","doi":"10.1177/10732748251353077","DOIUrl":"10.1177/10732748251353077","url":null,"abstract":"<p><p>The leucine-rich pentatricopeptide repeat-containing (LRPPRC) protein, a member of the pentatricopeptide repeat (PPR) family, is a mitochondria-associated protein that regulates various biological processes, including cell cycle progression and mitochondrial gene translation. LRPPRC has also been identified as an important causative gene in several mitochondrial diseases. N6-methyladenosine (m6A) is the most prevalent and extensive modification of mRNA in eukaryotes, playing a significant role in cellular proliferation, differentiation, and oncogenesis. As an m6A regulator, LRPPRC has been shown to play an important role in the development of various human metabolic diseases and malignant tumors. This review mainly focuses on summarizing the biological roles of LRPPRC in a variety of human malignant tumors, emphasizing the molecular mechanisms LRPPRC is involved in and its potential impact on tumor prognosis.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251353077"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-07-17DOI: 10.1177/10732748251359836
Yujie Niu, Xingchun Luo, Xiaoxiao Yang, Yuancheng Guo, Xiao Tang, Long Zhao, Jinli Jian, Bei Liu
IntroductionNucleophosmin 1 (NPM1), FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), and de novo methyl transferase 3 A (DNMT3A) triple-mutated acute myeloid leukemia (AML) represents a distinct entity with poor outcomes.MethodsWe explored the gene mutation spectrum and clinical characteristics of 165 AML patients retrospectively, particularly comparing patients with NPM1/FLT3-ITD/DNMT3A triple-mutations and those without.ResultsOur results demonstrated significantly elevated white blood cell counts (P < 0.001), bone marrow blast percentages (P = 0.037), and platelet counts (P = 0.007) in the triple-mutated cohort (6.7%) compared to the non-triple-mutated patients. Furthermore, all triple-mutated cases were classified as the M4/M5 subtype of the French-American-British classification (P = 0.017). Although no significant difference in complete remission rates was observed between the groups after initial treatment, the median overall survival for triple-mutated AML patients was only 4 months. Using the Gene Expression Omnibus (GEO) database and bioinformatics, we compared AMLNPM1mutFLT3-ITDmutDNMT3Amut and AMLNPM1mutFLT3-ITDmutDNMT3Awt. A total of 246 AML patients from the GEO dataset were included to evaluate the expression profiles of differentially expressed genes. The guanine nucleotide-binding protein subunit γ 4 (GNG4) was differentially expressed between AMLNPM1mutFLT3-ITDmutDNMT3Amut and AMLNPM1mutFLT3-ITDmutDNMT3Awt, which had the most adjacent nodes among hub genes. The prognostic value of GNG4 was further validated in AML patient samples through qRT-PCR.ConclusionClinical validation indicated a substantial downregulation of GNG4 in AMLNPM1mutFLT3-ITDmutDNMT3Amut compared to AMLNPM1mutFLT3-ITDmutDNMT3Awt patients. Thus, GNG4 may play a role in the low survival rate of AMLNPM1mutFLT3-ITDmutDNMT3Amut patients, offering novel insights into the prognosis, therapeutic targets, and prognostic evaluation of AML.
{"title":"Clinical Characteristics and Outcomes of Acute Myeloid Leukemia Patients Harboring <i>NPM1/FLT3-ITD/DNMT3A</i> Triple Mutations and the Potential Prognostic Value of <i>GNG4</i>.","authors":"Yujie Niu, Xingchun Luo, Xiaoxiao Yang, Yuancheng Guo, Xiao Tang, Long Zhao, Jinli Jian, Bei Liu","doi":"10.1177/10732748251359836","DOIUrl":"10.1177/10732748251359836","url":null,"abstract":"<p><p>IntroductionNucleophosmin 1 (<i>NPM1</i>), FMS-like tyrosine kinase 3-internal tandem duplication (<i>FLT3-ITD</i>), and de novo methyl transferase 3 A (<i>DNMT3A</i>) triple-mutated acute myeloid leukemia (AML) represents a distinct entity with poor outcomes.MethodsWe explored the gene mutation spectrum and clinical characteristics of 165 AML patients retrospectively, particularly comparing patients with <i>NPM1/FLT3-ITD/DNMT3A</i> triple-mutations and those without.ResultsOur results demonstrated significantly elevated white blood cell counts (<i>P</i> < 0.001), bone marrow blast percentages (<i>P</i> = 0.037), and platelet counts (<i>P</i> = 0.007) in the triple-mutated cohort (6.7%) compared to the non-triple-mutated patients. Furthermore, all triple-mutated cases were classified as the M4/M5 subtype of the French-American-British classification (<i>P</i> = 0.017). Although no significant difference in complete remission rates was observed between the groups after initial treatment, the median overall survival for triple-mutated AML patients was only 4 months. Using the Gene Expression Omnibus (GEO) database and bioinformatics, we compared AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut</sup> and AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>wt</sup>. A total of 246 AML patients from the GEO dataset were included to evaluate the expression profiles of differentially expressed genes. The guanine nucleotide-binding protein subunit γ 4 (<i>GNG4</i>) was differentially expressed between AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut</sup> and AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>wt</sup>, which had the most adjacent nodes among hub genes. The prognostic value of <i>GNG4</i> was further validated in AML patient samples through qRT-PCR.ConclusionClinical validation indicated a substantial downregulation of <i>GNG4</i> in AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut</sup> compared to AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>wt</sup> patients. Thus, <i>GNG4</i> may play a role in the low survival rate of AML<sup><i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut</sup> patients, offering novel insights into the prognosis, therapeutic targets, and prognostic evaluation of AML.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251359836"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-09-16DOI: 10.1177/10732748251378804
Jabed Iqbal
Breast cancer remains a critical public health challenge in low- and middle-income countries (LMICs), where late-stage diagnoses, limited access to care, and fragmented survivorship support exacerbate disparities in outcomes. This manuscript examines the systemic barriers to delivering women-centric breast cancer care in LMICs, including geographic and socioeconomic inequities, underfunded prevention efforts, and gaps in policy implementation. Building on a proposed roadmap for reform, we advocate for culturally adaptive strategies, community co-creation, and investment in scalable care models. By prioritizing women's unique needs and fostering multisectoral collaboration, LMICs can transform breast cancer care from survival-focused to empowerment-driven, even amid resource constraints.
{"title":"Women-Centric Breast Cancer Care in Low- and Middle-Income Countries: Challenges, Solutions, and a Roadmap for Equity.","authors":"Jabed Iqbal","doi":"10.1177/10732748251378804","DOIUrl":"10.1177/10732748251378804","url":null,"abstract":"<p><p>Breast cancer remains a critical public health challenge in low- and middle-income countries (LMICs), where late-stage diagnoses, limited access to care, and fragmented survivorship support exacerbate disparities in outcomes. This manuscript examines the systemic barriers to delivering women-centric breast cancer care in LMICs, including geographic and socioeconomic inequities, underfunded prevention efforts, and gaps in policy implementation. Building on a proposed roadmap for reform, we advocate for culturally adaptive strategies, community co-creation, and investment in scalable care models. By prioritizing women's unique needs and fostering multisectoral collaboration, LMICs can transform breast cancer care from survival-focused to empowerment-driven, even amid resource constraints.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251378804"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-09-12DOI: 10.1177/10732748251378666
Iffat Elbarazi, Luai A Ahmed
This editorial introduces the "Cancer Control" Special Collection featuring 14 peer-reviewed diverse studies from diverse geographical regions and thematic areas, including screening, HPV vaccination, cancer literacy, genetic and molecular innovations, and culturally tailored interventions. This collection highlights disparities in access, uptake, and awareness across populations emphasizing the urgent need for evidence-based strategies. It calls for integrated approaches in prevention, health education, policy reform, and technological advancements to reduce the global cancer burden, which continues to rise, especially in low- and middle-income countries.
{"title":"Alleviating the Global Burden of Cancer Through Prevention and Early Detection.","authors":"Iffat Elbarazi, Luai A Ahmed","doi":"10.1177/10732748251378666","DOIUrl":"10.1177/10732748251378666","url":null,"abstract":"<p><p>This editorial introduces the \"Cancer Control\" Special Collection featuring 14 peer-reviewed diverse studies from diverse geographical regions and thematic areas, including screening, HPV vaccination, cancer literacy, genetic and molecular innovations, and culturally tailored interventions. This collection highlights disparities in access, uptake, and awareness across populations emphasizing the urgent need for evidence-based strategies. It calls for integrated approaches in prevention, health education, policy reform, and technological advancements to reduce the global cancer burden, which continues to rise, especially in low- and middle-income countries.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251378666"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145055510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IntroductionColorectal cancer (CRC) is the third most common cancer worldwide and a significant public health threat with far-reaching societal implications. The currently available CRC therapeutic strategies have limitations, thus requiring the development of new strategies. Coxsackievirus B3 (CVB3) exhibits strong oncolytic activity in CRC, although its mechanism of action remains unclear. This study aimed to investigate whether the induction of ferroptosis is a promising treatment strategy for CRC and whether CVB3 could activate ferroptosis during infection.MethodsIn vitro and in vivo experiments were conducted to evaluate whether CVB3 infection activates the ferroptosis pathway by upregulating miR-214-3p to suppress glutathione peroxidase 4 (GPX4) expression. Dual-luciferase assays and rescue experiments were performed to confirm this regulatory mechanism. Clinical CRC tissues and colon cancer xenograft models were used to demonstrate the mediating role of the miR-214-3p/GPX4 axis in the interaction between viral replication and ferroptosis.ResultsCVB3 demonstrated oncolytic virus properties by selectively lysing tumor cells. The in vitro and in vivo experiments confirmed that CVB3 activates the ferroptosis pathway by upregulating miR-214-3p to suppress GPX4 expression, thereby promoting viral replication and tumor regression. Antagonizing miR-214-3p reversed this process.ConclusionmiR-214-3p expression was upregulated during CVB3 infection of CRC tissues and cells, activating the ferroptosis pathway and promoting tumor cell death.
{"title":"Coxsackievirus B3 Inhibited Colorectal Cancer by Upregulating miR-214-3P and Promoting Ferroptosis.","authors":"Shuang Zhu, Fangzhou Liu, Suwen Ou, Xin Tang, Zilong Guan, Guodong Sun, Songlin Ran, Jinhua Ye, Yanni Song, Rui Huang","doi":"10.1177/10732748251376088","DOIUrl":"10.1177/10732748251376088","url":null,"abstract":"<p><p>IntroductionColorectal cancer (CRC) is the third most common cancer worldwide and a significant public health threat with far-reaching societal implications. The currently available CRC therapeutic strategies have limitations, thus requiring the development of new strategies. Coxsackievirus B3 (CVB3) exhibits strong oncolytic activity in CRC, although its mechanism of action remains unclear. This study aimed to investigate whether the induction of ferroptosis is a promising treatment strategy for CRC and whether CVB3 could activate ferroptosis during infection.MethodsIn vitro and in vivo experiments were conducted to evaluate whether CVB3 infection activates the ferroptosis pathway by upregulating miR-214-3p to suppress glutathione peroxidase 4 (GPX4) expression. Dual-luciferase assays and rescue experiments were performed to confirm this regulatory mechanism. Clinical CRC tissues and colon cancer xenograft models were used to demonstrate the mediating role of the miR-214-3p/GPX4 axis in the interaction between viral replication and ferroptosis.ResultsCVB3 demonstrated oncolytic virus properties by selectively lysing tumor cells. The in vitro and in vivo experiments confirmed that CVB3 activates the ferroptosis pathway by upregulating miR-214-3p to suppress GPX4 expression, thereby promoting viral replication and tumor regression. Antagonizing miR-214-3p reversed this process.ConclusionmiR-214-3p expression was upregulated during CVB3 infection of CRC tissues and cells, activating the ferroptosis pathway and promoting tumor cell death.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251376088"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BackgroundColorectal cancer (CRC) predominantly affects older adults, whose treatment outcomes may be influenced by baseline health-related quality of life (HRQoL). This study aimed to identify predictors of poor preoperative HRQoL in older patients undergoing CRC surgery and to stratify them into risk groups.MethodsWe retrospectively analyzed data on patients aged ≥65 years who underwent radical CRC surgery at a single medical center in Taiwan (2016-2018). Preoperative HRQoL was assessed using the EORTC QLQ-ELD14 questionnaire and a comprehensive geriatric assessment. Patients were stratified into high or low HRQoL groups based on the median QLQ-ELD14 sum score. Logistic regression identified independent predictors of poor HRQoL, and recursive partitioning analysis (RPA) was applied for risk stratification.ResultsAmong the 179 patients, the most distressing HRQoL domains were Burden of Disease, Maintaining Purpose, and Worries about Others. Independent predictors of poor HRQoL included female sex (adjusted odds ratio [OR] = 2.41, P = 0.029), frailty (adjusted OR = 1.53, P = 0.042), poor Eastern Cooperative Oncology Group (ECOG) performance status (adjusted OR = 2.19, P = 0.008), and lower educational attainment (adjusted OR = 0.23, P = 0.019). RPA identified five patient subgroups with distinct risk levels; frail female had the highest risk (71.4%), while fit patients with college education or higher had the lowest (9.5%).ConclusionFrailty, functional status, sex, and education level are key determinants of preoperative HRQoL in older patients with CRC. The RPA provides a simple tool to identify high-risk patients, allowing targeted preoperative interventions to optimize care and enhance surgical outcomes.
结直肠癌(CRC)主要影响老年人,其治疗结果可能受到基线健康相关生活质量(HRQoL)的影响。本研究旨在确定接受结直肠癌手术的老年患者术前HRQoL差的预测因素,并将其划分为危险组。方法回顾性分析2016-2018年在台湾某医疗中心接受根治性结直肠癌手术的≥65岁患者资料。术前HRQoL评估采用EORTC QLQ-ELD14问卷和综合老年评估。根据QLQ-ELD14总分中位数将患者分为高HRQoL组和低HRQoL组。Logistic回归确定HRQoL差的独立预测因素,并应用递归划分分析(RPA)进行风险分层。结果179例患者HRQoL中最苦恼的域为疾病负担、维持目的和对他人的担忧。HRQoL差的独立预测因素包括女性(校正比值比[OR] = 2.41, P = 0.029)、体弱多病(校正比值比[OR] = 1.53, P = 0.042)、东部肿瘤合作组(ECOG)工作状态差(校正比值比= 2.19,P = 0.008)、受教育程度低(校正比值比= 0.23,P = 0.019)。RPA确定了五个具有不同风险水平的患者亚组;体弱多病的女性患病风险最高(71.4%),专科及以上学历的健康患者患病风险最低(9.5%)。结论老年结直肠癌患者术前HRQoL的主要影响因素为身体虚弱、功能状态、性别和文化程度。RPA提供了一个简单的工具来识别高危患者,允许有针对性的术前干预,以优化护理和提高手术效果。
{"title":"Predictors of Preoperative Quality of Life in Older Patients With Colorectal Cancer in Taiwan: A Retrospective Cohort Study.","authors":"Cheng-Chou Lai, Shih-Ying Chen, Shu-Huan Huang, Chun-Kai Liao, Hao-Wei Kou, Yi-Fu Chen, Yu-Shin Hung, Wen-Chi Chou","doi":"10.1177/10732748251397079","DOIUrl":"10.1177/10732748251397079","url":null,"abstract":"<p><p>BackgroundColorectal cancer (CRC) predominantly affects older adults, whose treatment outcomes may be influenced by baseline health-related quality of life (HRQoL). This study aimed to identify predictors of poor preoperative HRQoL in older patients undergoing CRC surgery and to stratify them into risk groups.MethodsWe retrospectively analyzed data on patients aged ≥65 years who underwent radical CRC surgery at a single medical center in Taiwan (2016-2018). Preoperative HRQoL was assessed using the EORTC QLQ-ELD14 questionnaire and a comprehensive geriatric assessment. Patients were stratified into high or low HRQoL groups based on the median QLQ-ELD14 sum score. Logistic regression identified independent predictors of poor HRQoL, and recursive partitioning analysis (RPA) was applied for risk stratification.ResultsAmong the 179 patients, the most distressing HRQoL domains were <i>Burden of Disease</i>, <i>Maintaining Purpose</i>, and <i>Worries about Others</i>. Independent predictors of poor HRQoL included female sex (adjusted odds ratio [OR] = 2.41, <i>P</i> = 0.029), frailty (adjusted OR = 1.53, <i>P</i> = 0.042), poor Eastern Cooperative Oncology Group (ECOG) performance status (adjusted OR = 2.19, <i>P</i> = 0.008), and lower educational attainment (adjusted OR = 0.23, <i>P</i> = 0.019). RPA identified five patient subgroups with distinct risk levels; frail female had the highest risk (71.4%), while fit patients with college education or higher had the lowest (9.5%).ConclusionFrailty, functional status, sex, and education level are key determinants of preoperative HRQoL in older patients with CRC. The RPA provides a simple tool to identify high-risk patients, allowing targeted preoperative interventions to optimize care and enhance surgical outcomes.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251397079"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12602925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}